Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
SAN DIEGO, March 10, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 12:30 p.m. PT on Wednesday, March 15, at the 29th Annual ROTH Conference (Newport Beach, California March 12 – 15). A webcast of the company’s presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Tony Ramos (858) 646-1127 Website: www.vical.com
